Skip to main content
Top
Published in: BMC Oral Health 1/2023

Open Access 01-12-2023 | Cushing's Syndrome | Case Report

Iatrogenic cushing’s syndrome post intralesional triamcinolone acetonide in oral submucous fibrosis: 2 case reports

Authors: Kuenga Choden, Tshewang Gyeltshen

Published in: BMC Oral Health | Issue 1/2023

Login to get access

Abstract

Background

Oral Submucous Fibrosis (OFMF) is an oral potentially malignant disorder (OPMDs), strongly linked to betel quid chewing. It exhibits a significantly higher rate of malignant transformation compared to other OPMDs. The use of Intralesional Triamcinolone Acetonide Injection has emerged as a highly effective treatment option and has become the cornerstone of managing this condition.

Case Presentation

A 44-year-old female and a 40-year-old male presented with burning sensation and limited mouth opening, leading to diagnosis of OSMF. Both patients were treated with Triamcinolone Acetonide (TAC) Intralesional injections. Following a few months of treatment, a significant improvement in mouth opening was observed. However, both patients began experiencing symptoms such as facial rounding (mooning of the face), a buffalo hump, uneven hair growth, and swelling in the lower extremities. Upon recognizing these symptoms as indicative of Cushing’s Syndrome, the administration of TAC injection was discontinued. Both patients were referred to a higher-level medical facility for confirmatory tests, which revealed elevated cortisol levels in both morning (Cortisol A.M) and evening (Cortisol P.M).

Conclusion

TAC injection has been established as an effective treatment for OSMF. However, it is crucial to closely monitor patients for any adverse effects resulting from the treatment, which may arise from high dosage or increased frequency.
Literature
2.
go back to reference Shen YW, Shih YH, Fuh LJ, Shieh TM. Oral Submucous fibrosis: a review on biomarkers, pathogenic mechanisms, and treatments. Int J Mol Sci. 2020;21(19):1–19.CrossRef Shen YW, Shih YH, Fuh LJ, Shieh TM. Oral Submucous fibrosis: a review on biomarkers, pathogenic mechanisms, and treatments. Int J Mol Sci. 2020;21(19):1–19.CrossRef
4.
go back to reference Rajendran R. Shafer’s Textbook of oral Pathology. Shafer’s Textb ORAL Pathol 2012;(January 2009):81–222. Rajendran R. Shafer’s Textbook of oral Pathology. Shafer’s Textb ORAL Pathol 2012;(January 2009):81–222.
12.
go back to reference Ali H, Ahmed S, Raza SH. Effect of Intralesional Injection of Triamcinolone Acetonide in oral sub-mucous fibrosis. 2019;24(December):6–10. Ali H, Ahmed S, Raza SH. Effect of Intralesional Injection of Triamcinolone Acetonide in oral sub-mucous fibrosis. 2019;24(December):6–10.
13.
go back to reference Gopinath D, Hui LM, Veettil SK, Balakrishnan Nair A, Maharajan MK. Comparative efficacy of interventions for the management of oral Submucous fibrosis: a systematic review and network Meta-analysis. J Pers Med. 2022;12(8). https://doi.org/10.3390/jpm12081272. Gopinath D, Hui LM, Veettil SK, Balakrishnan Nair A, Maharajan MK. Comparative efficacy of interventions for the management of oral Submucous fibrosis: a systematic review and network Meta-analysis. J Pers Med. 2022;12(8). https://​doi.​org/​10.​3390/​jpm12081272.
Metadata
Title
Iatrogenic cushing’s syndrome post intralesional triamcinolone acetonide in oral submucous fibrosis: 2 case reports
Authors
Kuenga Choden
Tshewang Gyeltshen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2023
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-023-03505-x

Other articles of this Issue 1/2023

BMC Oral Health 1/2023 Go to the issue